Before entering, confirm that you understand the conditions of this research catalog.
Information and products presented on this website are intended for laboratory, analytical and scientific research. They are not intended for diagnosis, treatment, prevention of disease, or administration to humans or animals.
Confirmation will be remembered on this device for 30 days.
Clear research summaries, substance mechanisms and laboratory topics without therapeutic claims.
Research & studies
The FDA expanded Mounjaro’s U.S. indication. What did the 13,299-participant SURPASS-CVOT trial show, and how should HR 0.92 be interpreted?
Read article →
Research & studies
A 2026 review of tirzepatide as a dual GIP/GLP-1 agonist, including SURMOUNT-5, long-term SURMOUNT-1, SURPASS-CVOT, SUMMIT and cardiovascular updates.
Read article →
Research & studies
Retatrutide activates GIP, GLP-1 and glucagon receptors. A September 2026 overview of the latest TRIUMPH and TRANSCEND results, safety data and next steps.
Read article →